THE Australian Commission on Safety and Quality in Health Care has created new fact sheets for clinicians and patients affected by the discontinuation of various insulin products in Australia.
Novo Nordisk discontinued the Protaphane InnoLet human insulin (rys) 100 IU/mL injection multidose cartridge on 01 Feb.
Pharmacists can dispense a Protaphane Penfill human insulin (rys) 100 IU/mL injection multidose cartridge in the place of a Protaphane InnoLet cartridge without a new prescription from the prescriber, under a Serious Scarcity Substitution Instrument (SSSI) created last year.
However, pharmacists should use their clinical judgement.
With other insulin product discontinuations also expected, healthcare providers will play a crucial role in helping minimise patient impact.
The fact sheets for clinicians and patients can be found HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Feb 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Feb 25
